Fulcrum Therapeutics, Inc.
FULC Healthcare Biotechnology
Fulcrum Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $80.0 million, up 2,752.0% from fiscal 2023. In the quarter to June 2026, EPS fell 21.4% and free cash flow fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow FULC
Fulcrum Therapeutics, Inc. (FULC) EV/Sales
As of 16 October 2026, Fulcrum Therapeutics, Inc. (FULC) trades at a EV/Sales of −0.5×. Over the past ten years it has ranged from −40.3× (April 2023) to 178× (March 2024); the current reading is higher than 13% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 0.6× | (99.17%) |
| FY2023 | 73.4× | 205.14% |
| FY2022 | 24.0× | 13.12% |
| FY2021 | 21.3× | 1.95% |
| FY2020 | 20.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2024 | 1.4× | (98.04%) |
| Dec 2023 | 73.4× | — |
| Sep 2023 | −1.6× | — |
| Jun 2023 | −24.4× | — |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FULC Fulcrum Therapeutics, Inc. | −0.5× |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | 1.4× |
| ABEO Abeona Therapeutics Inc. compare | 4.6× |
| SRZN Surrozen, Inc. compare | 14.9× |
| OCGN Ocugen, Inc. compare | 36.2× |
| EYPT EyePoint, Inc. compare | 40.8× |
| PALI Palisade Bio, Inc. compare | 230× |
| BNTC Benitec Biopharma Limited compare | 2,637× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)